Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2025 ,inter alia, to consider and approve matters related ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Venmax Drugs will meet on September 2, 2025 to consider a proposed merger with Hatri Pharma Private Limited, along with an increase in authorised share capital. The board will also approve the 36th AGM notice, director's report, and annual report for FY2024-25. Other agenda items include approving the secretarial auditor report, appointing a secretarial auditor for five years from FY2025-26, and inducting Mrs. Dakshita Jain as an additional non-executive independent director. The company is a small Hyderabad-based pharmaceutical firm listed on BSE (Scrip Code: 531015). No swap ratio, valuation, or scheme details for the proposed merger have been disclosed yet.
The proposed merger with Hatri Pharma is the most material item and could reshape the company's business, but this is only an initial proposal with no terms announced — shareholders should wait for the swap ratio and scheme details. The share capital increase and new independent director appointment are routine corporate housekeeping items ahead of the AGM.